Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × Neoplasms × Paclitaxel × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 9 Parkinson Disease 4, Autosomal Dominant Lewy Body 6 Breast Neoplasms 4 Fallopian Tube Neoplasms 3 Endometrial Neoplasms 3 Triple Negative Breast Neoplasms 2 Ovarian Neoplasms 2 Esophageal Neoplasms 2 Carcinoma, Ovarian Epithelial 2 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Ureteral Neoplasms 1 Recurrence 1 Neoplasms 1 Neoplasm Metastasis 1 Carcinosarcoma 1 Carcinoma 1 Brenner Tumor 1

Interventions

trametinib 3 encorafenib 3 dabrafenib 3 Oxaliplatin 3 zolbetuximab 2 selpercatinib 2 pembrolizumab 2 lenvatinib 2 larotrectinib 2 binimetinib 2 Leucovorin 2 Fulvestrant 2 Fluorouracil 2 Cetuximab 2 Capecitabine 2 trastuzumab deruxtecan 1 tepotinib 1 telisotuzumab vedotin 1 ribociclib 1 repotrectinib 1 relatlimab 1 pralsetinib 1 pegaspargase 1 niraparib 1 dostarlimab 1 blinatumomab 1 avelumab 1 asparaginase erwinia chrysanthemi recombinant 1 adagrasib 1 Vemurafenib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03981796 2025-09-03

RUBY

Tesaro, Inc.

Phase 3 Active not recruiting

785 enrolled 2 FDA

Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡